MedPath

Prolonged Vasospasm in Subarachnoid Hemorrhage

Completed
Conditions
Subarachnoid Hemorrhage
Vasospasm, Intracranial
Registration Number
NCT04193124
Lead Sponsor
Hospital El Cruce
Brief Summary

The prevalence and clinical implications of prolonged cerebral vasospasm in patients with subarachnoid hemorrhage are unknown.

Detailed Description

The prevalence and clinical importance of prolonged cerebral vasospasm (after day 21 of bleeding) in patients with subarachnoid hemorrhage is unknown.

Objectives: To determine the prevalence and clinical relevance of prolonged vasospasm in patients with subarachnoid hemorrhage secondary to cerebral aneurysm.

A prospective and observational study was conducted. Adult patients with a diagnosis of subarcnoid hemorrhage CT scan or presence of blood in the cerebrospinal fluid were incorporated. Patients with vasospasm were followed daily with transcranial doppler. Those with technical impossibility to perform transcranial and pregnant Doppler were excluded. Day 0 was defined, the day of the last bleeding.

Evaluation: 1) It was considered in patients with prolonged vasospasm: whether or not it was associated with clinical manifestation (deterioration of the sensory or new neurological deficit) and 2) the magnitude of the vasospasm (mild, moderate or severe) was measured by transcranial doppler.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
109
Inclusion Criteria

Subarachnoid hemorrhage -

Exclusion Criteria

Pregnancy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinical implication1 month

Presence or not of neurological symptoms related to intracranial vasospasm (delayed cerebral ischemia)

Gravity of vasospasm by transcranial doppler1 month

Mild, moderate and severe according to Aaslid scale

Secondary Outcome Measures
NameTimeMethod
Mortality assessmentsix monts

Mortality was assessed at hospital discharge and at six months

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.